Natural compounds as multitarget agents in Alzheimer’s diseases: evidence from in vivo and in vitro models
Frontiers in Pharmacology · 23.02.2026 · 17
DOI: 10.3389/fphar.2026.1766470 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.02.2026. Verfasst von Vicko Suswidiantoro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Programme, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Introduction
Alzheimer’s disease (AD), the most common cause of dementia, is marked by a gradual decline in cognitive function driven by amyloid-β (Aβ) deposition, tau hyperphosphorylation, synaptic failure, neuroinflammatory responses, and mitochondrial dysfunction. Despite extensive research efforts, currently available pharmacological treatments provide only limited symptomatic relief and do not prevent disease progression. These shortcomings have fuelled growing interest in natural compounds, which possess pleiotropic biological properties and may more effectively target the multifaceted pathology of AD.
Methods
This systematic review was performed in compliance with the PRISMA 2020 guidelines. Comprehensive literature searches were conducted across PubMed, Scopus, and ScienceDirect to identify preclinical and clinical studies examining the effects of natural compounds in in vitro and in vivo models relevant to AD. Eligible studies assessed phytochemicals, herbal formulations, marine-derived substances, or nutraceuticals and their impact on core AD-related pathological features.
Results
A total of 41 studies fulfilled the inclusion criteria, including 25 in vivo and 16 in vitro investigations. Across these studies, natural compounds consistently exhibited neuroprotective effects via multiple mechanisms associated with AD pathogenesis. These included the reduction of oxidative stress and neuroinflammation, inhibition of apoptotic pathways, modulation of amyloidogenic processes, attenuation of Aβ aggregation, regulation of tau-associated signalling, and preservation of synaptic function and cognitive outcomes.
Conclusion
Overall, the available evidence suggests that natural compounds confer multitarget neuroprotective effects that directly engage with key pathological mechanisms underlying AD. Nonetheless, significant translational challenges remain, particularly with respect to bioavailability, compound standardisation, and clinical efficacy. Further robust, well-controlled clinical trials are essential to establish the therapeutic value of these agents as potential disease-modifying interventions for AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral Programme, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
- School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.
- Faculty of Science, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom.
- Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, Indonesia.
- Integrative Pharmacogenomics Institute (iPROMISE), UiTM Selangor Branch, Bandar Puncak Alam, Selangor, Malaysia.
- Faculty of Pharmacy, UiTM Selangor Branch, Bandar Puncak Alam, Selangor, Malaysia.
Zitieren
APA
Suswidiantoro, V., Tang, K. S., Rahman, K., Ariestanti, D. M., James, R. J., Yan, C. C., Kato, M., & Saputri, F. C. (2026). Natural compounds as multitarget agents in Alzheimer’s diseases: evidence from in vivo and in vitro models. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1766470
Vancouver
Suswidiantoro V, Tang KS, Rahman K, Ariestanti DM, James RJ, Yan CC, et al. Natural compounds as multitarget agents in Alzheimer’s diseases: evidence from in vivo and in vitro models. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1766470
BibTeX
@article{Suswidiantoro2026,
author = {Suswidiantoro, Vicko and Tang, Kim San and Rahman, Khalid and Ariestanti, Donna Maretta and James, Richard Johari and Yan, Choo Chee and Kato, Mitsuyasu and Saputri, Fadlina Chany},
title = {Natural compounds as multitarget agents in Alzheimer’s diseases: evidence from in vivo and in vitro models},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1766470}
}
EUVIMED